140 related articles for article (PubMed ID: 31985116)
1. Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions.
Madison RW; Gupta SV; Elamin YY; Lin DI; Pal SK; Necchi A; Miller VA; Ross JS; Chung JH; Alexander BM; Schrock AB; Heymach JV; Reddy P; Ali SM
BJU Int; 2020 May; 125(5):739-746. PubMed ID: 31985116
[TBL] [Abstract][Full Text] [Related]
2. HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts.
Eriksson P; Sjödahl G; Chebil G; Liedberg F; Höglund M
Oncotarget; 2017 Jul; 8(30):48905-48914. PubMed ID: 28388586
[TBL] [Abstract][Full Text] [Related]
3.
Sakai K; Maeda S; Saeki K; Yoshitake R; Goto-Koshino Y; Nakagawa T; Nishimura R; Yonezawa T; Matsuki N
Vet Pathol; 2020 Jan; 57(1):56-65. PubMed ID: 31640537
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.
Ross JS; Wang K; Khaira D; Ali SM; Fisher HA; Mian B; Nazeer T; Elvin JA; Palma N; Yelensky R; Lipson D; Miller VA; Stephens PJ; Subbiah V; Pal SK
Cancer; 2016 Mar; 122(5):702-11. PubMed ID: 26651075
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma.
Isharwal S; Audenet F; Drill E; Pietzak EJ; Iyer G; Ostrovnaya I; Cha E; Donahue T; Arcila M; Jayakumaran G; Berger MF; Rosenberg JE; Bajorin DF; Coleman J; Dalbagni G; Reuter VE; Bochner BH; Solit DB; Al-Ahmadie HA
Eur Urol Focus; 2019 Mar; 5(2):201-204. PubMed ID: 28802642
[TBL] [Abstract][Full Text] [Related]
6. Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC.
Riess JW; Gandara DR; Frampton GM; Madison R; Peled N; Bufill JA; Dy GK; Ou SI; Stephens PJ; McPherson JD; Lara PN; Burich RA; Ross JS; Miller VA; Ali SM; Mack PC; Schrock AB
J Thorac Oncol; 2018 Oct; 13(10):1560-1568. PubMed ID: 29981927
[TBL] [Abstract][Full Text] [Related]
7. Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations.
Palsgrove DN; Taheri D; Springer SU; Cowan M; Guner G; Mendoza Rodriguez MA; Rodriguez Pena MDC; Wang Y; Kinde I; Ricardo BFP; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
Hum Pathol; 2019 Mar; 85():1-9. PubMed ID: 30447301
[TBL] [Abstract][Full Text] [Related]
8. Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations.
Choudhury NJ; Campanile A; Antic T; Yap KL; Fitzpatrick CA; Wade JL; Karrison T; Stadler WM; Nakamura Y; O'Donnell PH
J Clin Oncol; 2016 Jun; 34(18):2165-71. PubMed ID: 27044931
[TBL] [Abstract][Full Text] [Related]
9. Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience.
Rizzo A; Mollica V; Giunchi F; Dall'Olio FG; Rosellini M; Marchetti A; Franceschini T; Schiavina R; Brunocilla E; Fiorentino M; Ardizzoni A; Massari F
Pathol Res Pract; 2021 Apr; 220():153410. PubMed ID: 33765474
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM
Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617
[TBL] [Abstract][Full Text] [Related]
11. Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2.
Posada JM; Yakirevich E; Kamat AM; Sood A; Jacob JM; Bratslavsky G; Grivas P; Spiess PE; Li R; Necchi A; Mega AE; Golijanin DJ; Pavlick D; Huang RSP; Lin D; Danziger N; Sokol ES; Sivakumar S; Ross JS; Cheng L
Mod Pathol; 2024 Mar; 37(3):100424. PubMed ID: 38219954
[TBL] [Abstract][Full Text] [Related]
12. Spectrum of genomic alterations in FGFR3: current appraisal of the potential role of FGFR3 in advanced urothelial carcinoma.
Sethakorn N; O'Donnell PH
BJU Int; 2016 Nov; 118(5):681-691. PubMed ID: 27271022
[TBL] [Abstract][Full Text] [Related]
13. H-RAS mutation is a key molecular feature of pediatric urothelial bladder cancer. A detailed report of three cases.
Castillo-Martin M; Collazo Lorduy A; Gladoun N; Hyun G; Cordon-Cardo C
J Pediatr Urol; 2016 Apr; 12(2):91.e1-7. PubMed ID: 26522772
[TBL] [Abstract][Full Text] [Related]
14. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
15. Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype.
Zinnall U; Weyerer V; Compérat E; Camparo P; Gaisa NT; Knuechel-Clarke R; Perren A; Lugli A; Toma M; Baretton G; Kristiansen G; Wirtz RM; Cheng L; Wullich B; Stoehr R; Hartmann A; Bertz S
Hum Pathol; 2018 Oct; 80():55-64. PubMed ID: 29885409
[TBL] [Abstract][Full Text] [Related]
16. EGFR and erbB2 mutation status in Japanese lung cancer patients.
Sasaki H; Shimizu S; Endo K; Takada M; Kawahara M; Tanaka H; Matsumura A; Iuchi K; Haneda H; Suzuki E; Kobayashi Y; Yano M; Fujii Y
Int J Cancer; 2006 Jan; 118(1):180-4. PubMed ID: 16003726
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
Schrock AB; Li SD; Frampton GM; Suh J; Braun E; Mehra R; Buck SC; Bufill JA; Peled N; Karim NA; Hsieh KC; Doria M; Knost J; Chen R; Ou SI; Ross JS; Stephens PJ; Fishkin P; Miller VA; Ali SM; Halmos B; Liu JJ
J Thorac Oncol; 2017 Jun; 12(6):932-942. PubMed ID: 28315738
[TBL] [Abstract][Full Text] [Related]
18. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
19.
Klempner SJ; Madison R; Pujara V; Ross JS; Miller VA; Ali SM; Schrock AB; Kim ST; Maron SB; Dayyani F; Catenacci DVT; Lee J; Chao J
Oncologist; 2019 Nov; 24(11):1462-1468. PubMed ID: 31249137
[TBL] [Abstract][Full Text] [Related]
20. Human Epidermal Growth Factor Receptor 2 Overexpression in Micropapillary and Other Variants of Urothelial Carcinoma.
Behzatoğlu K; Yörükoğlu K; Demir H; Bal N
Eur Urol Focus; 2018 Apr; 4(3):399-404. PubMed ID: 28753766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
